IL112990A - Mutated viruses anti-viral compounds and novel methods of making vaccines - Google Patents

Mutated viruses anti-viral compounds and novel methods of making vaccines

Info

Publication number
IL112990A
IL112990A IL11299095A IL11299095A IL112990A IL 112990 A IL112990 A IL 112990A IL 11299095 A IL11299095 A IL 11299095A IL 11299095 A IL11299095 A IL 11299095A IL 112990 A IL112990 A IL 112990A
Authority
IL
Israel
Prior art keywords
novel methods
viral compounds
mutated viruses
making vaccines
viruses anti
Prior art date
Application number
IL11299095A
Other languages
English (en)
Other versions
IL112990A0 (en
Inventor
Dennis T Brown
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Publication of IL112990A0 publication Critical patent/IL112990A0/xx
Publication of IL112990A publication Critical patent/IL112990A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14Fungi; Culture media therefor
    • C12N1/16Yeasts; Culture media therefor
    • C12N1/18Baker's yeast; Brewer's yeast
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36111Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36121Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36111Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL11299095A 1994-03-21 1995-03-14 Mutated viruses anti-viral compounds and novel methods of making vaccines IL112990A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/213,860 US5532154A (en) 1994-03-21 1994-03-21 Mutated alpha virus

Publications (2)

Publication Number Publication Date
IL112990A0 IL112990A0 (en) 1995-06-29
IL112990A true IL112990A (en) 1999-11-30

Family

ID=22796796

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11299095A IL112990A (en) 1994-03-21 1995-03-14 Mutated viruses anti-viral compounds and novel methods of making vaccines

Country Status (14)

Country Link
US (1) US5532154A (ja)
EP (1) EP0755440A4 (ja)
JP (1) JP3821484B2 (ja)
KR (1) KR100394163B1 (ja)
CN (1) CN1122105C (ja)
AU (1) AU688887B2 (ja)
CA (1) CA2186044C (ja)
FI (1) FI963717A (ja)
IL (1) IL112990A (ja)
NZ (1) NZ283575A (ja)
RU (1) RU2194754C2 (ja)
SA (1) SA95150618B1 (ja)
WO (1) WO1995025788A1 (ja)
ZA (1) ZA952259B (ja)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US6465634B1 (en) 1996-04-05 2002-10-15 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
WO1998051297A1 (en) * 1997-05-14 1998-11-19 The University Of New Mexico Inhibition of cell surface protein disulfide isomerase
US7128915B2 (en) * 1997-09-18 2006-10-31 Research Development Foundation Membrane virus host range mutations and their uses as vaccine substrates
US7335363B2 (en) * 1997-09-18 2008-02-26 Research Development Foundation Membrane virus host range mutations and their uses as vaccine substrates
AU757549B2 (en) * 1998-03-27 2003-02-27 Cytos Biotechnology Ag Inducible alphaviral gene expression system
US6451579B1 (en) 1998-07-29 2002-09-17 Invitrogen Corporation Regulated expression of recombinant proteins using RNA viruses
EP1175497B1 (en) * 1999-04-14 2010-04-07 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
US8647864B2 (en) * 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
US6890487B1 (en) 1999-09-30 2005-05-10 Science & Technology Corporation ©UNM Flow cytometry for high throughput screening
US7416903B2 (en) * 1999-09-30 2008-08-26 Stc.Unm Wavy interface mixer
US6498189B1 (en) 1999-11-10 2002-12-24 University Of New Mexico Method for induction of L-selectin shedding
AU1647501A (en) 1999-12-10 2001-06-18 Cytos Biotechnology Ag Replicon based activation of endogenous genes
AU2001256609A1 (en) * 2000-05-12 2001-11-20 Cyril John Higgins Method of organized retrieval of world-wide web pages
AU2001275191A1 (en) * 2000-05-31 2001-12-11 Chiron Corporation Method for the purification of alphavirus replicon particles
NZ523831A (en) * 2000-07-13 2005-10-28 Invitrogen Corp Methods and compositions for rapid protein and peptide extraction and isolation using a lysis matrix
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
EP1660631B1 (en) * 2003-08-01 2013-04-24 Life Technologies Corporation Compositions and methods for purifying short rna molecules
JP2008538362A (ja) * 2005-04-12 2008-10-23 ロマーク ラボラトリーズ エル.シー. タンパク質の成熟の遮断を介して疾患を処置するための方法、タンパク質ジスルフィドイソメラーゼなどの分子シャペロンの機能を阻害する、またはグリコシル化を妨害する化合物、それらを含む薬学的組成物、および治療剤を同定するためのスクリーニング方法
US20110195089A1 (en) * 2008-10-08 2011-08-11 The Adminstrators Of The Tulane Educational Fund Compositions, methods, and kits for enhancing the immunogenicity of pathogenic antigens
EP2432869B1 (en) 2009-05-21 2020-08-12 Essen Instruments, Inc. d/b/a Essen BioScience, Inc. System and method for separating samples in a continuous flow
US9752964B1 (en) 2009-06-22 2017-09-05 Stc.Unm Flow cytometry apparatus pulling sample stream through observation chamber
RU2720518C1 (ru) * 2018-12-18 2020-04-30 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Штамм вируса лихорадки Синдбис 1383 клон 3 (Sindbis fever virus 1383 clone 3)
CA3170611A1 (en) * 2020-03-13 2021-09-16 Nuo-Beta Pharmaceutical Technology (Shanghai) Co. Ltd Anti-coronavirus effect and application of pi4k inhibitor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2072125C (en) * 1989-10-31 2000-05-23 Robert J. Gorelick Design and construction of non-infectious human retroviral mutants deficient in genomic rna
WO1994004185A2 (en) * 1992-08-19 1994-03-03 Trustees Of Boston University Method of inhibiting reduction of disulfide bonds

Also Published As

Publication number Publication date
WO1995025788A1 (en) 1995-09-28
NZ283575A (en) 2001-03-30
FI963717A (fi) 1996-11-20
CA2186044A1 (en) 1995-09-28
CN1122105C (zh) 2003-09-24
KR100394163B1 (ko) 2004-10-20
FI963717A0 (fi) 1996-09-19
SA95150618B1 (ar) 2006-04-22
ZA952259B (en) 1996-09-20
KR970701778A (ko) 1997-04-12
AU2191395A (en) 1995-10-09
AU688887B2 (en) 1998-03-19
EP0755440A4 (en) 1998-08-19
JP3821484B2 (ja) 2006-09-13
JPH09510613A (ja) 1997-10-28
CA2186044C (en) 2005-08-23
IL112990A0 (en) 1995-06-29
CN1144536A (zh) 1997-03-05
EP0755440A1 (en) 1997-01-29
US5532154A (en) 1996-07-02
RU2194754C2 (ru) 2002-12-20

Similar Documents

Publication Publication Date Title
IL112990A (en) Mutated viruses anti-viral compounds and novel methods of making vaccines
PL324906A1 (en) Vaccines against viral hepatitis of c type
CS20091A2 (en) Basic calciumaluminiumhydroxidedicarboxylate, method of its preparation and its application
IL113850A0 (en) Process and intermediates for the preparation of 3-aryluracils
GB9415369D0 (en) Mutant virus
PL318193A1 (en) Novel streptogramines and method of obtaining them by mutasynthesis
EP0446578A3 (en) Methods for the preparation of silanes and polysilanes
IL97867A0 (en) Process for the preparation of indolones and intermediates therefor
HU901571D0 (en) Vaccine and diagnostics against the virus of pig-cholera
EP0259617A3 (en) Process and preparation for inactivating viruses
GB9010359D0 (en) Enzyme and its preparation
AU678404B2 (en) Process for the purification and concentration of rubella virus
EP0440078A3 (en) Process for the preparation of retinylglycosides and intermediates for this process
ZA911652B (en) Virus free platelet derivative and method of making same
NZ295530A (en) Preparation of 1-halo-3-trialkylsilanyl-benzenes
EP0564212A3 (en) Process for the preparation of arylethylamines and substituted arylethylamines
GB9026655D0 (en) Improved hose and method of manufacture thereof
EP0456658A4 (en) Vinyloxy hydroxyalkylcycloalkane and preparation therefor
EP0564213A3 (en) Process for the preparation of arylethylamines and substituted arylethylamines
HU9400634D0 (en) Vaccine and diagnosticum against parvovirosis of gooses and barbari duks
BG98272A (en) Preparation and method for the treatment of virus hepatitis
GB8914680D0 (en) Prevention of aid virus
GB8926058D0 (en) Framing means and joints therefor
HU9400767D0 (en) Ceramie covers of chimney and producing them
CS29090A2 (en) //5-substituted-4-oxo-4h-pyran-2-yl/methyl-chloroacetates and method of their preparation

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees